Skip to content
10-Q

Quarterly Report

AN2 Therapeutics, Inc. ANTX

0001193125-26-216755

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 36.02M sh
Shares Diluted Q1 2026 · Mar 31, 2026 34.06M sh
Shares Diluted Q1 2026 · Mar 31, 2025 30.05M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$12.07M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$10.62M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $53.49M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $19.94M
Stockholders Equity Q1 2026 · Mar 31, 2026 $81.76M
Stockholders Equity Q1 2026 · Dec 31, 2025 $53.06M
Stockholders Equity Q1 2026 · Mar 31, 2025 $73.33M
Stockholders Equity Q1 2026 · Dec 31, 2024 $81.85M
Current Liabilities Q1 2026 · Mar 31, 2026 $5.56M
Current Liabilities Q1 2026 · Dec 31, 2025 $8.72M
Total Liabilities Q1 2026 · Mar 31, 2026 $5.73M
Total Liabilities Q1 2026 · Dec 31, 2025 $8.89M
Current Assets Q1 2026 · Mar 31, 2026 $87.49M
Current Assets Q1 2026 · Dec 31, 2025 $59.94M
Total Assets Q1 2026 · Mar 31, 2026 $87.49M
Total Assets Q1 2026 · Dec 31, 2025 $61.95M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.29
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.35
Eps Basic Q1 2026 · Mar 31, 2026 −$0.29
Eps Basic Q1 2026 · Mar 31, 2025 −$0.35
Sga Expense Q1 2026 · Mar 31, 2026 $3.81M
Sga Expense Q1 2026 · Mar 31, 2025 $3.85M
Rd Expense Q1 2026 · Mar 31, 2026 $6.74M
Rd Expense Q1 2026 · Mar 31, 2025 $7.69M
Net Income Q1 2026 · Mar 31, 2026 −$10.03M
Net Income Q1 2026 · Mar 31, 2025 −$10.65M
Operating Income Q1 2026 · Mar 31, 2026 −$10.55M
Operating Income Q1 2026 · Mar 31, 2025 −$11.54M